%0 Journal Article
%A Elez, Elena
%A Gomez-España, Maria Auxiliadora
%A Gravalos, Cristina
%A Garcia-Alfonso, Pilar
%A Ortiz-Morales, Maria Jose
%A Losa, Ferran
%A Diaz, Inmaculada Ales
%A Graña, Begoña
%A Toledano-Fonseca, Marta
%A Valladares-Ayerbes, Manuel
%A Polo, Eduardo
%A Salgado, Mercedes
%A Martinez de Castro, Eva
%A Safont, Maria Jose
%A Salud, Antonieta
%A Ruiz-Casado, Ana
%A Tabernero, Josep
%A Riesco, Maria Del Carmen
%A Rodriguez-Ariza, Antonio
%A Aranda, Enrique
%T Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial.
%D 2021
%U http://hdl.handle.net/10668/19521
%X Aflibercept is an antiangiogenic drug against metastatic colorectal cancer (mCRC) combined with 5-fluorouracil/leucovorin/irinotecan (FOLFIRI); however, no antiangiogenic biomarker has yet been validated. We assessed aflibercept plus FOLFIRI, investigating the biomarker role of baseline vascular endothelial growth factor A (VEGF-A) and angiotensin-converting enzyme (ACE). Phase II trial in oxaliplatin-treated mCRC patients who received aflibercept plus FOLFIRI. The reported 135 ng/mL ACE cut-off was used and ROC analysis was performed to assess the optimal VEGF-A cut-off for progression-free survival (PFS). Overall survival (OS), time to progression (TTP), time to treatment failure (TTF), overall response rate (ORR) and disease control rate (DCR) were also assessed. In total, 101 patients were followed for a median of 12 (6-17) months. The 1941 pg/mL VEGF-A was an optimal cut-off, with a longer median PFS when VEGF-A was  This study supports aflibercept plus FOLFIRI benefits, suggesting VEGF-A as a potential biomarker to predict better outcomes.
%K Biomarkers
%K Colorectal neoplasms
%K Fluorouracil
%K Vascular endothelial growth factor A
%~